MicroRNAs (miRNAs) have emerged as powerful regulators of the genome and, through concerted efforts to identify their function and evaluate their ability to alter cell growth in vitro and in vivo, some have gained favor as potential therapeutics. Although these miRNA-based approaches can revolutionize the way that tumors are diagnosed and treated, our understanding of the functional and the molecular aspects of miRNA biology are still incomplete. Moreover, in order to bridge miRNA biology with clinical utility, the challenges that still remain with regard to in vivo delivery of miRNAs must be tackled. To address these challenges we propose two Specific Aims: I. To enhance miRNA therapeutic efficacy through combinatorial miRNA-based targeting and molecular profiling and II. To develop and test second-generation vehicles for delivery of unprotected miRNAs. Our extensive preliminary evidence supports both Aims. We recently identified 10 miRNAs out of 2,019 that significantly enhance the tumor suppressive activity of miR-34a, the first miRNA to enter into clinical trial, and have begun to identify the direct targets of these miRNAs to gain insight into the molecular reason for the cooperative effect. We used a novel method that relies on ligating the cellular miRNAs directly to their associated RNA target followed by deep sequencing of the RNA hybrids. The sequencing data from 13 libraries that we constructed will be used to identify the direct targets of these miRNAs, independent of current algorithms. Targets will be validated and evaluated for pathways that they associate with that will begin to explain their cooperative effect with miR-34a. We also propose to evaluate the in vivo efficacy of the combinatorial pairs using various models of lung cancer. Although we are committed to understanding how these miRNAs are cooperating with miR-34a we also propose to use this data to better understand miRNA biology at a global level. Thus, our data will be used to determine how miRNAs associate with their targets at nucleotide resolution, and how the target population changes with regard to miRNA concentration, which is extremely important to understand as miRNA clinical utility increases. In parallel we will develop and test a second-generation miRNA delivery vehicle, which is a first-in-class method for delivering miRNAs completely unprotected. Following systemic delivery using this method, the miRNA accumulates specifically in the tumor and is efficiently taken up by the tumorigenic cells as indicated by target gene repression with no obvious toxicity. Collectively, the data obtained from this work will validate in vivo efficacy for combinatorial miRNA therapeutics, and for the first time will provide evidence for unprotected miRNA delivery. We will also begin to break down the barriers regarding miRNA target identification that until now has been mostly approached using algorithms that lack critical parameters due to a gap in our understanding of how miRNAs bind their targets.

Public Health Relevance

The project is relevant to the NIH's mission and to public health because successful completion of this work will allow us to identify mechanisms involved in improving miR-34a therapeutic efficacy and miRNA delivery in general that will ultimately lead to enhancing and lengthening the life of individuals inflicted with NSCLC and other cancers. These studies have the potential to provide a better understanding of the molecular pathology of lung and other cancers, knowledge that can lead to significant improvements in cancer treatment and ultimate cure rates in the long term. While this is an emerging field, the benefit to our understanding of miRNAs in cancer will be enormous if we can better understand and harness these natural growth suppressors as anti-cancer agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA205420-01A1
Application #
9247601
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Kondapaka, Sudhir B
Project Start
2017-09-30
Project End
2022-08-31
Budget Start
2017-09-30
Budget End
2018-08-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Purdue University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Rangasamy, Loganathan; Chelvam, Venkatesh; Kanduluru, Ananda Kumar et al. (2018) New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange. Bioconjug Chem 29:1047-1059
Zhou, Wenqing; Pal, Arpita S; Hsu, Alan Yi-Hui et al. (2018) MicroRNA-223 Suppresses the Canonical NF-?B Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation. Cell Rep 22:1810-1823
Orellana, Esteban A; Tenneti, Srinivasarao; Rangasamy, Loganathan et al. (2017) FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Sci Transl Med 9:
Orellana, Esteban A; Kasinski, Andrea L (2017) No vehicle, no problem. Oncotarget 8:96470-96471